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Background: Recent meta-analysis has demonstrated that statin treatment might be effective on preventing a new onset of atrial fibrillation (AF). 
We have reported liner relationship between the duration of P wave (Ad) in P-wave signal-averaged electrocardiogram (P-SAECG) and the extent 
of atrial fibrosis (a substrate for AF). We conducted an open-label prospective randomized study in patients with hypercholesterolemia to test the 
efficacy of statin on Ad in P-SAECG (UMIN CTR C000003824).
Methods: Forty patients with hypercholesterolemia were randomized to receive pitavastatin 2mg/day (group S) or ezetimibe 10mg/day (group 
E) for 12 months. In group E, patients were coadministered with fenofibrate if not fulfilling the guideline. P-SAECG was recorded at baseline and 12 
months after drug intervention, and changes in Ad were evaluated.
Results: LDL-C was equally decreased in both groups. While Ad decreased in group S (-2.2±9.9 msec), Ad in group E increased (4.6±8.8 msec)
(difference between the groups, p=0.0303). Multivariate analysis showed that predictors of shortening of Ad were lower hs-CRP (p=0.0098), higher 
HbA1c (p=0.0219), lower serum creatinine (p=0.0378) at baseline, and the treatment with pitavastatin (p=0.0122).
Conclusions: Treatment with standard dose of pitavastatin decreased Ad in P-SAECG, which can translate into reduced atiral fibrosis. This study 
showed a possibility of statin as the upstream therapy for AF in patients with hypercholesterolemia.
 
